Abstract
A novel coronavirus (MERS-CoV) related to SARS-CoV recently emerged in the Middle East causing more than 400 deaths with a mortality rate of about 30%, much higher than SARS-CoV. Both viruses target epithelial cells in the respiratory tract, although utilizing different cellular receptors. Because of the sporadic nature of the MERS outbreak and difficulty in collecting randomized, controlled clinical data, the objective of this review was to focus on published in vitro and in vivo drug sensitivity data using both cell lines and available animal models of SARS/MERS CoV infection. Determination of drug activity was based on achievable serum levels in humans relative to in vitro IC50 (50% inhibitory concentration) or EC50 (50% effective concentration) drug concentrations. The most active drugs against SARS/MERS CoV at clinically achievable serum levels were type I interferons and a TLR3 agonist, interferon inducer/activator.
Keywords: Antivirals, Cmax, coronaviruses, EC50, IC50, interferons, MERS, SARS.
Infectious Disorders - Drug Targets
Title:Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans
Volume: 14 Issue: 1
Author(s): David R. Strayer, Robert Dickey and William A. Carter
Affiliation:
Keywords: Antivirals, Cmax, coronaviruses, EC50, IC50, interferons, MERS, SARS.
Abstract: A novel coronavirus (MERS-CoV) related to SARS-CoV recently emerged in the Middle East causing more than 400 deaths with a mortality rate of about 30%, much higher than SARS-CoV. Both viruses target epithelial cells in the respiratory tract, although utilizing different cellular receptors. Because of the sporadic nature of the MERS outbreak and difficulty in collecting randomized, controlled clinical data, the objective of this review was to focus on published in vitro and in vivo drug sensitivity data using both cell lines and available animal models of SARS/MERS CoV infection. Determination of drug activity was based on achievable serum levels in humans relative to in vitro IC50 (50% inhibitory concentration) or EC50 (50% effective concentration) drug concentrations. The most active drugs against SARS/MERS CoV at clinically achievable serum levels were type I interferons and a TLR3 agonist, interferon inducer/activator.
Export Options
About this article
Cite this article as:
Strayer R. David, Dickey Robert and Carter A. William, Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans, Infectious Disorders - Drug Targets 2014; 14 (1) . https://dx.doi.org/10.2174/1871526514666140713152858
DOI https://dx.doi.org/10.2174/1871526514666140713152858 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Understanding the Role of Corona Virus based on Current Scientific Evidence - A Review with Emerging Importance in Pandemic
Recent Patents on Anti-Infective Drug Discovery Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management
Current Pharmaceutical Design Initial Remedial Action to Coronavirus in India: A Study
Current Respiratory Medicine Reviews Discovery of Potential Inhibitors of the Receptor-binding Domain (RBD) of Pandemic Disease-causing SARS-CoV-2 Spike Glycoprotein from Triphala Through Molecular Docking
Current Chinese Chemistry Thymosin α1; Potential Therapeutic Implications of an Immunoregulatory Drug in the Treatment of Lymphocytopenia Associated with COVID-19
Current Immunology Reviews (Discontinued) Forecasting of COVID-19 Cases in India: A Predictive Study
Current Immunology Reviews (Discontinued) Computer-Aided Perspective for the Design of Flexible HIV Non- Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): de-novo Drug Design, Virtual Screening and Molecular Dynamics Simulations
Letters in Drug Design & Discovery SARS: Understanding the Virus and Development of Rational Therapy
Current Molecular Medicine Good Uptake of the COVID-19 Vaccine among Patients with Rheumatic Diseases in the United Arab Emirates (UAE)
New Emirates Medical Journal Structure Based Drug Design Approach to Identify Potential SARS-CoV-2 Polymerase Inhibitors
Coronaviruses The Role of Nanoparticles as Nanocarriers for the Controlled Release of some Potential Existing Antiviral Drugs for SARS-CoV-2 Management: A Review
Coronaviruses China Coronavirus Outbreak: All the Latest Updates
Current Topics in Medicinal Chemistry The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology 3D-QSAR Studies on Flavone-8-acetic Acid Derivatives of Aminopeptidase N Inhibitors
Medicinal Chemistry Developments in Antiviral Drug Design, Discovery and Development in 2004
Current Drug Targets - Infectious Disorders New Approaches to Drug-DNA Interactions Based on Graphical Representation and Numerical Characterization of DNA Sequences
Current Computer-Aided Drug Design Phytochemical Informatics and Virtual Screening of Herbs Used in Chinese Medicine
Current Pharmaceutical Design Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin
Current Drug Safety Research and Patents on Coronavirus and COVID-19: A Review
Recent Patents on Nanotechnology COVID-19: Small-Molecule Clinical Trials Landscape
Current Topics in Medicinal Chemistry